Olodaterol + tiotropium resulted in significant improvements over tiotropium + placebo in FEV1 AUC0-3 ( treatment differences : 0.117 L [ P < 0.001 ] , ANHELTO 1 ; 0.106 L [ P < 0.001 ] , ANHELTO 2 ) and trough FEV1 ( treatment differences : 0.062 L [ P < 0.001 ] , ANHELTO 1 ; 0.040 L [ P = 0.0029 ] , ANHELTO 2 ) ; these were supported by secondary end points .